Literature DB >> 11560568

Recovery of platelet function after discontinuation of clopidogrel treatment in healthy volunteers.

A A Weber1, M Braun, T Hohlfeld, B Schwippert, D Tschöpe, K Schrör.   

Abstract

AIMS: To study the recovery of platelet function after discontinuation of clopidogrel treatment in healthy volunteers.
METHODS: Ten healthy volunteers were treated with clopidogrel (75 mg day(-1)) for 7 days. CD62P expression and PAC-1 binding were measured by flow cytometry.
RESULTS: Adenosine diphosphate (ADP, 30 microM)-induced platelet responses were almost completely inhibited by clopidogrel. After discontinuation of the drug, platelet function gradually increased and complete recovery was seen 7 days after the last clopidogrel dose. The mean difference (95% CI) for ADP-induced PAC-1 binding (fluorescence intensity) between baseline and 7 days after the last dose was 0.01 (0.61, -0.59). Single cell analysis provides direct evidence for an irreversible mode of action of clopidogrel.
CONCLUSIONS: This is the first report to directly demonstrate irreversibility of clopidogrel action in humans.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11560568      PMCID: PMC2014541          DOI: 10.1046/j.0306-5251.2001.01453.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  10 in total

1.  Repeated-dose pharmacodynamics of clopidogrel in healthy subjects.

Authors:  J J Thebault; G Kieffer; G D Lowe; W S Nimmo; R Cariou
Journal:  Semin Thromb Hemost       Date:  1999       Impact factor: 4.180

2.  Identification and biological activity of the active metabolite of clopidogrel.

Authors:  P Savi; J M Pereillo; M F Uzabiaga; J Combalbert; C Picard; J P Maffrand; M Pascal; J M Herbert
Journal:  Thromb Haemost       Date:  2000-11       Impact factor: 5.249

3.  Non-specific inhibition of ADP-induced platelet antiaggregation by clopidogrel in vitro.

Authors:  J M Herbert; P Savi
Journal:  Thromb Haemost       Date:  1999-07       Impact factor: 5.249

Review 4.  Platelets.

Authors:  J N George
Journal:  Lancet       Date:  2000-04-29       Impact factor: 79.321

Review 5.  European Working Group on Clinical Cell Analysis: Consensus protocol for the flow cytometric characterisation of platelet function.

Authors:  G Schmitz; G Rothe; A Ruf; S Barlage; D Tschöpe; K J Clemetson; A H Goodall; A D Michelson; A T Nurden; T V Shankey
Journal:  Thromb Haemost       Date:  1998-05       Impact factor: 5.249

6.  Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signaling by the antiplatelet drug clopidogrel.

Authors:  J Geiger; J Brich; P Hönig-Liedl; M Eigenthaler; P Schanzenbächer; J M Herbert; U Walter
Journal:  Arterioscler Thromb Vasc Biol       Date:  1999-08       Impact factor: 8.311

7.  Pharmacokinetic profile of 14C-labeled clopidogrel.

Authors:  R Lins; J Broekhuysen; J Necciari; X Deroubaix
Journal:  Semin Thromb Hemost       Date:  1999       Impact factor: 4.180

8.  Specific inhibition of ADP-induced platelet aggregation by clopidogrel in vitro.

Authors:  A A Weber; S Reimann; K Schrör
Journal:  Br J Pharmacol       Date:  1999-01       Impact factor: 8.739

Review 9.  Ticlopidine and clopidogrel.

Authors:  M J Quinn; D J Fitzgerald
Journal:  Circulation       Date:  1999-10-12       Impact factor: 29.690

Review 10.  Clopidogrel.

Authors:  A J Coukell; A Markham
Journal:  Drugs       Date:  1997-11       Impact factor: 9.546

  10 in total
  25 in total

1.  Continuation of Dual Antiplatelet Therapy in a Patient with a Coronary Artery Stent with Dengue Hemorrhagic Fever: A Clinical Conundrum.

Authors:  N D B Ehelepola; A A S D Athurupana; P G C S Bowatte; Wasantha P Dissanayake
Journal:  Am J Trop Med Hyg       Date:  2020-01       Impact factor: 2.345

2.  Bridging therapy for early surgery in patients on dual antiplatelet therapy after drug-eluting stent implantation.

Authors:  E G Marcos; A C Da Fonseca; S H Hofma
Journal:  Neth Heart J       Date:  2011-10       Impact factor: 2.380

3.  [Periinterventional antiplatelet therapy: from bench to bedside].

Authors:  D Braun; C Schulz; D Sibbing; S Massberg
Journal:  Herz       Date:  2012-03       Impact factor: 1.443

4.  Is Taking an Antiplatelet Agent a Contraindication for Early Surgery in Displaced Femur Neck Fracture?

Authors:  Hyun-Seung Yoo; Young-Ho Cho; Young-Soo Byun; Min-Guek Kim
Journal:  Hip Pelvis       Date:  2015-09-30

Review 5.  Prevention and management of TURP-related hemorrhage.

Authors:  Liam E Kavanagh; Gregory S Jack; Nathan Lawrentschuk
Journal:  Nat Rev Urol       Date:  2011-08-16       Impact factor: 14.432

6.  Right middle cerebral artery aneurysm posted for clipping on dual anti-platelet therapy.

Authors:  Satyen Parida; Sandeep Kumar Mishra; K Sudeeep; Aahok Shankar Badhe
Journal:  Indian J Anaesth       Date:  2010-01

Review 7.  The efficacy and safety of perioperative antiplatelet therapy.

Authors:  J Christopher Merritt; Deepak L Bhatt
Journal:  J Thromb Thrombolysis       Date:  2002-04       Impact factor: 2.300

Review 8.  The efficacy and safety of perioperative antiplatelet therapy.

Authors:  J Christopher Merritt; Deepak L Bhatt
Journal:  J Thromb Thrombolysis       Date:  2004-02       Impact factor: 2.300

9.  A survey of the peri-operative management of urological patients on clopidogrel.

Authors:  Gaurav Mukerji; Indumina Munasinghe; Asif Raza
Journal:  Ann R Coll Surg Engl       Date:  2009-04-02       Impact factor: 1.891

10.  Antiplatelet drugs and the perioperative period: What every urologist needs to know.

Authors:  Pawan Vasudeva; Apul Goel; Vengetesh K Sengottayan; Satyanarayan Sankhwar; Divakar Dalela
Journal:  Indian J Urol       Date:  2009-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.